The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02530138 |
Recruitment Status : Unknown
Verified August 2015 by Dr Azita Hekmatdoost, National Nutrition and Food Technology Institute.
Recruitment status was: Recruiting
First Posted : August 20, 2015
Last Update Posted : August 20, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Introduction: Currently, Nonalcoholic Fatty Liver Disease (NAFLD) is the most common liver disease in the world. The only approved treatment for it is lifestyle modification and weight loss; however, there is no evidence for patients with normal or low body mass index (BMI).
The aim of this study is to evaluate the efficacy of symbiotic supplementation in NAFLD patients with normal or low BMI.
Methods and analysis: In this randomized, double-blind, placebo-controlled clinical trial protocol, 21 cases and 21 controls will be individually matched based on age and sex. This 42 patients with NAFLD will be supplemented twice daily for 28 wk with either a synbiotic or a placebo capsule. Both groups will be advised to follow an energy balanced diet and physical activity recommendations.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Alcoholic Steatohepatitis | Dietary Supplement: synbiotic Dietary Supplement: Placebo | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 42 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Study Start Date : | August 2014 |
Estimated Primary Completion Date : | February 2016 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Synbiotic
2 synbiotic capsules for 28 weeks
|
Dietary Supplement: synbiotic
2 symbiotics capsules per day for 28 weeks |
Placebo Comparator: maltodexterin
two capsules per day for 28 weeks
|
Dietary Supplement: Placebo
2 placebo capsules per day for 28 weeks |
- Alaninaminotransferase (ALT) (UL) [ Time Frame: 28 weeks ]by biochemical method
- hepatic steatosis (cap score) [ Time Frame: 28 weeks ]using transient elastography
- Body Mass Index (BMI) (kg/m2) [ Time Frame: 28 weeks ]using formula

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age of 18 to 70 years
- Body Mass Index (BMI) below 25
- Serum alaninaminotransferase more than 1.5 fold of upper limit of normal range
- Sonographic findings compatible with hepatic steatosis (degree 2 or more)
Exclusion Criteria:
- Diabetes
- Taking any kind of antibiotics two weeks before recruitment
- History of alcohol consumption
- pregnancy or lactation
- Professional athletes
- Other liver disease (viral/etc)
- Use of drugs such as calcium channel blockers, high dose synthetic estrogens, methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs, lipid-lowering agents, metformin and vitamin E
- A history of Hypertension, Cardiovascular disease, Pulmonary disease, Renal disease & Celiac disease; Cirrhosis
- History of Upper GI surgery / Prior surgical procedures such as jejunoileal or jejunocolic bypass, gastroplasty
- Following program to lose weight in recent 3 mo
- A history of hypothyroidism or Cushing's syndrome

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02530138
Contact: Azita Hakmatdost, MD, PhD | 9123065084 | a_hekmat2000@yahoo.com |
Iran, Islamic Republic of | |
NNFTRI clinic | Recruiting |
Tehran, Iran, Islamic Republic of, 19435 | |
Contact: Azita Hekmatdoost, MD, PhD 9123065084 a_hekmat2000@yahoo.com |
Responsible Party: | Dr Azita Hekmatdoost, associate prof, National Nutrition and Food Technology Institute |
ClinicalTrials.gov Identifier: | NCT02530138 |
Other Study ID Numbers: |
563 |
First Posted: | August 20, 2015 Key Record Dates |
Last Update Posted: | August 20, 2015 |
Last Verified: | August 2015 |
Fatty Liver Non-alcoholic Fatty Liver Disease Liver Diseases Digestive System Diseases |